ZYDUSLIFE Zydus Lifesciences Ltd Expansion Plans Announcement 2025 - USFDA Approval Zydus Lifesciences has received USFDA approval to conduct a Phase II(b) clinical trial for Usnoflast, targeting 210 patients with ALS over a 36-week treatment period to assess efficacy and safety..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd